HC Wainwright Reiterates Buy Rating on Dianthus Therapeutics, Sets $158 Target
HC Wainwright reiterated its Buy rating and $158 price target on Dianthus Therapeutics. The target implies 111.3% upside from the Oct. 14 close of $74.76.
HC Wainwright reiterated its Buy rating and $158 price target on Dianthus Therapeutics. The target implies 111.3% upside from the Oct. 14 close of $74.76.